Comparative Pharmacology
Head-to-head clinical analysis: BUTALAN versus PENTOBARBITAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALAN versus PENTOBARBITAL SODIUM.
BUTALAN vs PENTOBARBITAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalan is an ergot alkaloid derivative that acts as a partial agonist at serotonin (5-HT2B) receptors and an antagonist at alpha-adrenergic and dopamine (D2) receptors. It also inhibits prolactin secretion by stimulating dopamine receptors in the pituitary.
Enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, prolonging chloride channel opening and inhibiting neuronal firing.
1-2 tablets (50-100 mg butalbital, 325-650 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not exceeding 6 tablets per day.
Induction of anesthesia: 100-150 mg IV given over 30-60 seconds; additional increments of 25-50 mg as needed. Hypnotic/sedative: 100-300 mg IM or 150-200 mg PO at bedtime. Anticonvulsant in emergencies: 5-7 mg/kg IV slow push over 1-2 minutes, may repeat every 15-30 minutes up to a maximum of 1 g. Rectal administration: 120-200 mg as a single dose for sedation.
None Documented
None Documented
4-6 hours (terminal); prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life of 20-30 hours in adults. In prolonged ICU sedation, context-sensitive half-life can extend significantly (up to 50-100 hours) due to redistribution and accumulation.
Primarily renal (70% unchanged, 20% as metabolites); fecal 10%
Primarily renal excretion of inactive metabolites (hepatic metabolism via CYP). Approximately 25-50% unchanged in urine at alkaline pH; biliary/fecal elimination minimal (<5%).
Category C
Category D/X
Barbiturate
Barbiturate